PHM1N Stock Chart & Stats
$1780.91
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$1,608.38 - $1,780.91
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
$27.89B
Enterprise Value$1.40K
Total Cash (Recent Filing)$167.85M
Total Debt (Recent Filing)$47.54M
Price to Earnings (P/E)17.0
Beta0.08
Next Earnings
Jul 29, 2026EPS Estimate
3.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.65
Shares Outstanding18,000,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)5.12
Price to Sales (P/S)5.82
P/FCF Ratio29.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)40.14
Revenue Forecast (FY)$4.09B
Bulls Say, Bears Say
Bulls Say
High Profit MarginsSustained high gross and net margins indicate durable pricing power and cost structure advantages in marketed oncology products and IP licensing. Strong margins improve internal funding for R&D and reduce reliance on external capital, supporting long-term strategy and reinvestment.
Improved Free Cash FlowMaterial positive FCF provides lasting financial flexibility to fund clinical programs, commercial expansion, and milestone-linked activities without immediate dilution. Reliable cash generation supports operational continuity and strengthens negotiating leverage with potential partners.
Conservative Leverage And Equity GrowthLow leverage and stronger equity position give balance sheet resilience to absorb development setbacks and invest in pipeline opportunities. Conservative debt limits refinancing risk and enhances capacity to pursue partnerships or M&A when strategic opportunities arise.
Bears Say
Revenue And Profit VolatilityHistoric swings in revenue and profitability reflect sensitivity to product launches, market uptake, and one-off events. This cyclical performance raises predictability concerns for cash flows and planning over the medium term, complicating long-range budgeting and investor visibility.
Inconsistent Cash ConversionAlthough FCF is now positive, past negative free cash flow and weak cash conversion ratios point to earnings quality and timing gaps. If R&D or commercial spend rises, the company may need external funding or to rely on partner payments, increasing financial flexibility risk.
Dependence On Clinical/regulatory MilestonesCore revenues and milestone income hinge on successful trials, approvals, and partner deals. Such dependencies create structural binary risk: delays or failures can sharply reduce revenue and licensing receipts, making multi-quarter forecasts and steady revenue progression uncertain.
Pharma Mar SA News
PHM1N FAQ
What was Pharma Mar SA’s price range in the past 12 months?
Pharma Mar SA lowest stock price was $1608.38 and its highest was $1780.91 in the past 12 months.
What is Pharma Mar SA’s market cap?
Pharma Mar SA’s market cap is $27.89B.
When is Pharma Mar SA’s upcoming earnings report date?
Pharma Mar SA’s upcoming earnings report date is Jul 29, 2026 which is in 5 days.
How were Pharma Mar SA’s earnings last quarter?
Pharma Mar SA released its earnings results on Apr 23, 2026. The company reported $1.794 earnings per share for the quarter, missing the consensus estimate of $2.492 by -$0.698.
Is Pharma Mar SA overvalued?
According to Wall Street analysts Pharma Mar SA’s price is currently Undervalued.
Does Pharma Mar SA pay dividends?
Pharma Mar SA does not currently pay dividends.
What is Pharma Mar SA’s EPS estimate?
Pharma Mar SA’s EPS estimate is 3.55.
How many shares outstanding does Pharma Mar SA have?
Pharma Mar SA has 18,000,000 shares outstanding.
What happened to Pharma Mar SA’s price movement after its last earnings report?
Pharma Mar SA reported an EPS of $1.794 in its last earnings report, missing expectations of $2.492. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Pharma Mar SA?
Currently, no hedge funds are holding shares in MX:PHM1N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pharma Mar SA Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-3.20%
12-Months-Change
Fundamentals
Return on Equity
1.21%
Trailing 12-Months
Asset Growth
23.22%
Trailing 12-Months
Company Description
Pharma Mar SA
Pharma Mar, S.A., a biopharmaceutical firm established in 1986 and headquartered in Madrid, Spain, is dedicated to the research, development, production, and global sale of marine-derived bioactive compounds. Its primary focus is oncology, with operations spanning Spain, Italy, Germany, Ireland, the wider European Union, the United States, and other international markets. The company's activities are organized into three key segments: Oncology, Diagnostics, and RNA interference. Among its developed and commercialized treatments are Yondelis, prescribed for soft tissue sarcomas and ovarian cancer; Aplidin, targeting multiple myeloma; and Zepzelca, used for patients with small cell lung cancer. Furthermore, Pharma Mar is advancing PM14, currently in Phase II clinical trials for various solid tumors. Beyond pharmaceuticals, the company manufactures and markets diagnostic kits and is involved in creating therapeutic drugs designed to reduce or silence gene expression.